Login
Companies $EQ
$1.23 +$0.08 (6.96%) After hours
Equillium, Inc. logo

Equillium, Inc.

equilliumbio.com

What Do They Do?

Develops experimental medicines for people with severe autoimmune and inflammatory disorders, including gastrointestinal and inflammatory lung diseases.

Who Are Their Customers?

Ono paid for an exclusive option to acquire Equillium’s itolizumab rights and funded its development; Equillium had not established commercial sales or distribution capabilities.

How Are They Changing?

Pipeline focus The older report described active clinical programs spanning peptide inhibitors and an antibody. The latest centers on preclinical therapies for gastrointestinal disease, with an AhR modulator as the main development priority.

Partnership arrangements The older report described Ono’s option and development funding for itolizumab alongside a Biocon license; the latest says Ono’s option expired and the Biocon agreements ended, and reports no product sales.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support